Why is the Polynovo share price on ice today?

Polynovo shares aren't trading today. Let's take a look at what's going on.

The All Ordinaries Index (ASX: XAO) is enjoying some time in the sun today. At the time of writing, the All Ords has gained a healthy 0.5%, putting it back over 7,370 points. But one ASX All Ords share is missing out on the party today. That would be the Polynovo Ltd (ASX: PNV) share price.

Polynovo shares aren't trading today. The company finished at $2.09 a share yesterday afternoon, a level it will be staying at for a while. So what's going on with this ASX healthcare share that has it barred from trading?

Well, Polynovo released an ASX announcement this morning before market open that tells us some of what is going on.

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt

Image source: Getty Images

Polynovo share price frozen amid capital raise

So yes, Polynovo shares are suspended from trading at the request of the company. The purpose of this suspension is to allow Polynovo to conduct a capital raise.

This will be in three stages. The first is a $30 million institutional share placement for institutional investors. The second is a $17 million share purchase plan, available for retail investors. The third is a $3 million share placement available only to certain directors of the company.

All up, the $47 million that Polynovo hopes to raise will:

Accelerate growth in the US and the rest of the world, including the newest markets in Canada, India and Hong Kong… This will also include the construction of a new manufacturing and R&D facility, next to the existing [Melbourne] factory, to satisfy the significant increase in demand for NovoSorb.

Eligible shareholders will have the option to apply for up to $30,000 in new Polynovo shares at a price of $1.90 each, a 9.1% discount to the company's last traded share price of $2.09.

For retail investors, the new shares issued under the placement will start trading on 21 December next month. Polynovo expects its shares to resume ASX trading tomorrow.

The Polynovo share price is up almost 34% year to date in 2022 thus far. It's also up more than 130% since May.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »